Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use
Legislation that requires prescribers to check Ohio's Prescription Drug Monitoring Program was found to lead to a reduction in the quantity of opioids and benzodiazepines dispensed.
Hydrolysis of urine before benzodiazepine immunoassay screening and optimization of the immunoassay absorbance cutoff were found to improve the rate of false-negative screening.
A review of several published studies showed that the evidence did not support dose limitations or arbitrary caps of buprenorphine or methadone as a strategy to address benzodiazepine or other CNS depressant use in MAT-treated patients.
Continuous infusions of midazolam plus morphine do not provide additional pain relief compared with intermittent dosing of those drugs, and may increase hospital length of stay among pediatric patients who have undergone cardiac surgery.
The FDA has recently issued a report advising against the use of buprenorphine and methadone medications in patients taking benzodiazepines and/or other central nervous system depressants.
Patients with Alzheimer disease who were receiving benzodiazepines had a risk for pneumonia 30% greater than that of matched control patients.
Concurrent benzodiazepine and opioid use increased by 80% between 2001 and 2013 in the United States and significantly contributes to the overall population risk of opioid overdose.
Dr Fudin discusses concerns he has regarding the CDC guideline for prescribing opioids for chronic pain.
Short-term memory loss may be yet another price of America's opioid addiction epidemic.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds